Head and Neck Cancer Pathways

Patient Name:_____ Date of Birth:_____

Member Number: _____ Treatment Start Date:_____

Pathology:_____ **Stage**:_____

Line of Therapy: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op **ECOG Performance Status**:_____ ICD-10 Code:_____

__1st Line __2nd Line

Non-Nasopharyngeal (Squamous Cell Carcinoma) | Candidate for Local Therapy (M0) | Primary Systemic Therapy or Post-Operative Systemic Therapy

___High dose cisplatin* with concurrent RT

Non-Nasopharyngeal (Squamous Cell Carcinoma) | Metastatic and Recurrent Disease | First Line of Therapy (1st line)

___Carboplatin, fluorouracil (5FU), and cetuximab (Erbitux)

___Cisplatin, fluorouracil (5FU), and cetuximab (Erbitux)

Non-Nasopharyngeal (Squamous Cell Carcinoma) | Metastatic and Recurrent Disease | Second and Subsequent Lines of Therapy (2nd line+)

___Nivolumab (Opdivo)†

___Paclitaxel[23]

Nasopharynx | Candidate for Local Therapy (M0) | Primary Systemic Therapy

___High dose cisplatin* with concurrent RT

Nasopharynx | Metastatic and Recurrent Disease | First and Subsequent Lines of Therapy (1st Line+)

___Carboplatin

___Cisplatin

___Cisplatin‡ and gemcitabine (Gemzar)

___Cisplatin‡ and paclitaxel

___Fluorouracil (5FU)

___Gemcitabine (Gemzar)

___Gemcitabine (Gemzar) and vinorelbine (Navelbine)

___Methotrexate

___Paclitaxel

*High dose cisplatin refers to dosing to achieve total dose of 200-300 mg/m^2 of cisplatin over the course of the radiotherapy. There are several different appropriate cisplatin schedules that may be used.

†Administered at a dose of 240 mg every 2 weeks or 480 mg every 4 weeks

‡Substitution of carboplatin for cisplatin, and vice-versa, is acceptable for metastatic disease

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

AIM SpecialtyHealth
8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 11/28/2017 | Effective date: 2/5/2018